PureTech Health's Vedanta Biosciences raises $50m

PureTech Health said Vedanta Biosciences, its business pioneering the development of a new class of therapies designed to modulate the human microbiome, has raised $50m in new equity investments.

Proceeds would be used to advance multiple clinical studies in infectious and autoimmune diseases and to scale the company's technology platform.

New investors Rock Springs Capital, Invesco Asset Management and Health For Life Capital (Seventure) were joined by PureTech in the financing.

Puretech, whose shares were up almost 3%, is a cross-disciplinary healthcare company developing medicines at the interface of the gut, brain and immune system.